NCT05394103View on ClinicalTrials.gov

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

August 30, 2026

Conditions
Advanced CancerMetastatic Cancer
Interventions
DRUG

Q901

The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter

DRUG

KEYTRUDA® (pembrolizumab)

KEYTRUDA® (pembrolizumab) will be administered Q6W

Trial Locations (11)

32224

RECRUITING

Mayo Clinic, Jacksonville

55905

RECRUITING

Mayo Clinic, Rochester

60611

RECRUITING

Northwestern University, Chicago

75230

RECRUITING

Mary Crowley Cancer Research, Dallas

85054

RECRUITING

Mayo Clinic, Phoenix

90033

RECRUITING

University of Southern California, Los Angeles

07960

RECRUITING

Atlantic Health System Hospital, Morristown

Unknown

RECRUITING

National Cancer Center, Goyang-si

RECRUITING

CHA University Bundang Medical Center, Seongnam-si

NOT_YET_RECRUITING

Asan Medical Center, Seoul

NOT_YET_RECRUITING

Severance Hospital, Seoul

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Qurient Co., Ltd.

INDUSTRY